{
    "clinical_study": {
        "@rank": "146148", 
        "arm_group": [
            {
                "arm_group_label": "7vPnC (3-, 4-, 5-, 12-Month)", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "13vPnC (3-, 4-, 5-, 12-Month)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "13vPnC (2-, 4-, 6-, 12-Month)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "13vPnC (3-, 5-, 12-Month)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is primarily designed to evaluate the IgG immune responses to the 13 pneumococcal\n      serotypes induced by 13vPnC compared with the immune responses induced by 7vPnC when\n      measured 1 month after the infant series, and to evaluate the acceptability of the safety\n      profile of 13vPnC as measured by the incidence rates of local reactions, systemic events and\n      adverse events."
        }, 
        "brief_title": "A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pneumococcal Infection", 
        "condition_browse": {
            "mesh_term": "Pneumococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment.\n\n          2. Healthy infant as determined by medical history, physical examination, and judgment\n             of the investigator.\n\n        Exclusion Criteria:\n\n          1. Previous vaccination with licensed or investigational pneumococcal  vaccine.\n\n          2. A previous anaphylactic reaction to any vaccine or vaccine-related component.\n\n          3. Contraindication to vaccination with pneumococcal vaccines."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "77 Days", 
            "minimum_age": "42 Days"
        }, 
        "enrollment": {
            "#text": "1674", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692886", 
            "org_study_id": "B1851015", 
            "secondary_id": "6096A1-3019"
        }, 
        "intervention": [
            {
                "arm_group_label": "7vPnC (3-, 4-, 5-, 12-Month)", 
                "description": "suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively", 
                "intervention_name": "7-valent Pneumococcal Conjugate Vaccine", 
                "intervention_type": "Biological", 
                "other_name": "7vPnC"
            }, 
            {
                "arm_group_label": "13vPnC (3-, 4-, 5-, 12-Month)", 
                "description": "suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively", 
                "intervention_name": "13-valent Pnumococcal Conjugate vaccine", 
                "intervention_type": "Biological", 
                "other_name": "13vPnC"
            }, 
            {
                "arm_group_label": "13vPnC (2-, 4-, 6-, 12-Month)", 
                "description": "suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively", 
                "intervention_name": "13-valent Pnumococcal Conjugate vaccine", 
                "intervention_type": "Biological", 
                "other_name": "13vPnC"
            }, 
            {
                "arm_group_label": "13vPnC (3-, 5-, 12-Month)", 
                "description": "suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively", 
                "intervention_name": "13-valent Pnumococcal Conjugate vaccine", 
                "intervention_type": "Biological", 
                "other_name": "13vPnC"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "13vPnC", 
            "7vPnC", 
            "Healthy subjects", 
            "China"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851015&StudyName=A%20Study%20Evaluating%2013-Valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29%20In%20Healthy%20Infants%20In%20China"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huaian City", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "223300"
                    }, 
                    "name": "Jiangsu Province Huaiyin District Center for Disease prevention and Control"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huaian City", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "223100"
                    }, 
                    "name": "Jiangsu Province Hongze County Center for Disease prevention and Control"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lianshui County", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "223400"
                    }, 
                    "name": "Jiangsu Province Lianshui County Center for Disease prevention and Control"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210009"
                    }, 
                    "name": "Jiangsu Provincial Center for Disease Prevention and Control"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yishan Town, Guanyun County", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "222200"
                    }, 
                    "name": "Jiangsu Province Guanyun County Center for Disease prevention and Control"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 3, Randomized, Active-controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13vPnC Vaccine Compared With a 7vPnC in Healthy Infants in China", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level \u22650.35 mcg/mL 1 Month After the Infant Series in Group 1 And Group 2.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level \u22650.35 mcg/mL 1 Month After the Infant Series in Group 3.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (7 Months of age)"
            }, 
            {
                "measure": "Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 1 and Group 2.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 3.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (7 Months of age)"
            }, 
            {
                "measure": "Percentage of Participants Reporting Adverse Events in Group 1 and Group 2.", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 16 months from the participation into the study to the end of study"
            }, 
            {
                "measure": "Percentage of Participants Reporting Adverse Events in Group 3 and Group 4.", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 16 months from the participation into study to the end of study"
            }, 
            {
                "measure": "Percentage of Participants Reporting Pre-Specified Local Reactions In the 7 Days After Each Pneumococcal Vaccination in Group 1 and Group 2.", 
                "safety_issue": "Yes", 
                "time_frame": "Seven days after each pneumococcal vaccination dose within the period up to 12 months"
            }, 
            {
                "measure": "Percentage of Participants Reporting Pre-Specified Local Reactions In the 7 Days After Each Pneumococcal Vaccination in Group 3 and Group 4.", 
                "safety_issue": "Yes", 
                "time_frame": "Seven days after each pneumococcal vaccination dose within the period up to 12 months"
            }, 
            {
                "measure": "Percentage of Participants Reporting Pre-Specified Systemic Events (Including The Use Of Antipyretic Medication) In the 7 Days After Each Pneumococcal Vaccination in Group 1 and Group 2.", 
                "safety_issue": "Yes", 
                "time_frame": "Seven days after each pneumococcal vaccination dose within the period up to 12 months"
            }, 
            {
                "measure": "Percentage of Participants Reporting Pre-Specified Systemic Events (Including The Use Of Antipyretic Medication) In the 7 Days After Each Pneumococcal Vaccination in Group 3 and Group 4.", 
                "safety_issue": "Yes", 
                "time_frame": "Seven days after each pneumococcal vaccination dose within the period up to 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692886"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer \u2265 Lower Limit Of Quantitation (LLOQ) 1 Month After the Infant Series in Group 1 And Group 2.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer \u2265 Lower Limit Of Quantitation (LLOQ) 1 Month After the Infant Series in Group 3.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (7 Months of age)"
            }, 
            {
                "measure": "Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series in Group 1 and Group 2.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series in Group 3.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (7 Months of age)"
            }, 
            {
                "measure": "Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose in Group 2 and Group 3.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the toddler dose (13 Months of age)"
            }, 
            {
                "measure": "Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer \u2265 Lower Limit Of Quantitation (LLOQ) 1 Month After the Toddler Dose in Group 2 and Group 3.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the toddler dose (13 Months of age)"
            }, 
            {
                "measure": "Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Toddler Dose in Group 2 and Group 3.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the toddler dose (13 Months of age)"
            }, 
            {
                "measure": "Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level \u22650.35 mcg/mL 1 Month After the Infant Series in Group 4.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 4.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose in Group 4.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the toddler dose (13 Months of age)"
            }, 
            {
                "measure": "Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer \u2265 Lower Limit Of Quantitation (LLOQ) 1 Month After the Infant Series in Group 4.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer \u2265 Lower Limit Of Quantitation (LLOQ) 1 Month After the Toddler Dose in Group 4.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the toddler dose (13 Months of age)"
            }, 
            {
                "measure": "Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series in Group 4.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the infant series (6 Months of age)"
            }, 
            {
                "measure": "Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Toddler Dose in Group 4.", 
                "safety_issue": "No", 
                "time_frame": "1 month after the toddler dose (13 Months of age)"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}